ginkgo biloba neo #30 caps
Paramedical mean
Generic (International
Nonproprietary Name): Ginkgo Biloba
ATC
Code: N06DX02.
Drug form: Capsules.
Composition: dry extract of leaves of Ginkgo
Biloba – 40 mg (24% the flavonoid glycosides, 6% terpene lactones).
Excipients: magnesium
carbonate, lactose, povidone, aerosil.
Pharmacotherapeutic group: Phytogenous angioprotective drug.
Clinical- : Brain and peripheral blood circulation
improvement drug.
Pharmacological operation: ,,Ginkgo
Biloba neo’’ is a phytogenous drug. Active substances of the extract - flavonoid glycosides and terpene
lactones (Gingkolides and Bilobalides) regulate metabolism in the cells,
improve rheological indicators of blood and microcirculation. Medicine is
characterized by anti-hypotoxic activity on the tissues: supplies a brain and
peripheral tissue with oxygen and glucose, improves blood circulation in the
brain, it has cerebroprotective action, promotes decrease of permeability of the walls
of vessels (anti-edematous action in the brain and peripheral tissues),
interferes aggregation of platelets.
Indication:
Ø various etiology discirculatory
encephalopathy (stroke, craniocerebral trauma, elderly age) that is followed
by:
• Lowering of attention;
• Decrease of memory;
• Lowering of intellectual capacities;
• Feeling of fear;
• Sleep disturbance;
Ø Peripheral circulation and microcirculation
disorder (including arteriopathy of lower extremities);
Ø Raynaud syndrome;
Ø Neurosensory disorders (dizziness, tinnitus, hypacusia).
Contraindications: Abnormal ability of blood clotting; stomach
and duodenal ulcer disease; erosive gastritis; acute blood circulation disorder
in the brain; acute myocardial infarction; arterial hypotension; age of 18
years; hypersensitivity toward the compounding components of medicine;
pregnancy and lactation period.
Special indications: It is not recommended to take alcohol
together with the drug.
Taking of preparation during pregnancy and lactation
is not recommended, but its negative effect on the fetus is not established.
Side effects: In rare cases may detect allergic reactions
(rash on the skin), dyspepsia, headache, decreased blood clotting.
Dose and administration: Capsules are taken orally with water.
1-2 capsules are taken three times in a day.
Improvement of the condition is observed after a month. Duration of treatment -
not less than 3 months. If necessary, it is possible to continue a course of
treatment (after consultation with a doctor).
Overdose: Overdose cases of preparation isn’t
available.
Interaction
with other medicinal products: Co-administration of GINKGO BILOBA NEO with
acetylsalicylic acid or anticoagulants is not advisable.
Influence on cars and other
vehicles: The preparation
does not influence on driving cars and other
Production form:
Primary
package: 10
capsules in pvc/alu blister.
Secondary package: 3 blisters in a cardboard box with the application instruction.
Validity: 3 years.
In case of visual defects and expiry of
validity date, the preparation can not
be used.
Storage conditions: Store at a temperature no more than 25°C,
in a dark, dry place and keep away from
children.
Order
of issue: Pharmaceutical
product group III, issued without a prescription.
Manufacturer: "Neopharmi" LTD.
12th km, David Agmashenebeli alley,
Tbilisi, Georgia
Tel/Fax: +995 (032) 259-64-46; 259-57-90.